What’s the current market cap for Theravance Biopharma stock?

Theravance Biopharma (TBPH) has a market cap of $841m as of June 16, 2026.

What is the P/E ratio for Theravance Biopharma stock?

The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 7.38 as of June 16, 2026.

Does Theravance Biopharma stock pay dividends?

No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Theravance Biopharma dividend payment date?

Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Theravance Biopharma?

Theravance Biopharma (TBPH) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Theravance Biopharma stock | $TBPH Share Price

13:30

15:10

16:45

18:25

20:00

About Theravance Biopharma

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Ticker

$TBPH

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

South San Francisco, United States

Website

www.theravance.com

TBPH Metrics

BasicAdvanced

$841m

7.38

$2.21

0.19

What the Analysts think about TBPH

Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.

Bulls say / Bears say

In Q1 2026, YUPELRI collaboration revenue rose 15% year-over-year to $17.7 million, fueled by a 7% increase in U.S. net sales to $62.4 million, driven by stronger hospital channel uptake and improved pricing.

Full-year 2025 YUPELRI net sales increased 12% to $266.6 million, reflecting solid commercial momentum and broad market adoption of Theravance’s key COPD therapy.

All Hatch-Waxman litigation concerning YUPELRI was settled in March 2026 through an agreement with Mankind Pharma, ensuring exclusivity until April 23, 2039, and removing near-term generic competition risk.

Ampreloxetine’s Phase 3 CYPRESS trial failed to meet its primary endpoint, resulting in the discontinuation of the program and raising concerns about the company’s pipeline diversification and future growth prospects.

Theravance posted a GAAP diluted EPS loss of $0.10 in Q1 2026, missing analysts’ consensus estimate of a $0.03 profit by $0.13, underscoring ongoing profitability struggles outside its main product.

Theravance’s Q1 2026 revenue was entirely from its Viatris partnership on YUPELRI, exposing the company to concentration risk if partner performance or market dynamics shift.

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

TBPH Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TBPH Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TBPH

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Full-year 2025 YUPELRI net sales increased 12% to $266.6 million, reflecting solid commercial momentum and broad market adoption of Theravance’s key COPD therapy.

Theravance’s Q1 2026 revenue was entirely from its Viatris partnership on YUPELRI, exposing the company to concentration risk if partner performance or market dynamics shift.

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.